Divestment

Zealand Pharma

Zealand Pharma developed peptide drugs for type 2 diabetes.

Responsible partner
News

Key Facts

Sector: Life Sciences
Country: Denmark
Fund: LSP 3
Entry: 2005
Exit: 2013

Responsible Partner

René R. Kuijten

René R. Kuijten

Partner, Head of EQT Life Sciences

News

October 22, 2025
EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics
October 22, 2025
EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion
September 30, 2025
EQT Life Sciences portfolio company Merus to be acquired by Genmab in an all-cash USD 8.0 billion transaction
September 16, 2025
EQT Life Sciences portfolio company VarmX partners with CSL in a strategic collaboration and option agreement worth up to USD 2.2 billion

Do You Want to Know More?

We are eager to explore how we can achieve great things together.